{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T22:38:05Z","timestamp":1786747085381,"version":"build-2736575974"},"reference-count":104,"publisher":"American Chemical Society (ACS)","issue":"12","license":[{"start":{"date-parts":[[2020,11,10]],"date-time":"2020-11-10T00:00:00Z","timestamp":1604966400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2020,11,10]],"date-time":"2020-11-10T00:00:00Z","timestamp":1604966400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2020,11,10]],"date-time":"2020-11-10T00:00:00Z","timestamp":1604966400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-045"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30 CA016059"],"award-info":[{"award-number":["P30 CA016059"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002383","name":"King Saud University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002383","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000078","name":"Division of Materials Research","doi-asserted-by":"publisher","award":["DRM-1508363"],"award-info":[{"award-number":["DRM-1508363"]}],"id":[{"id":"10.13039\/100000078","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Center for Pharmaceutical Engineering and Sciences, Virginia Commonwealth University"},{"DOI":"10.13039\/501100011821","name":"Ministry of Education - Kingdom of Saudi Arabia","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100011821","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,12,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The lungs are major sites of metastases for several cancer types, including breast cancer (BC). Prognosis and quality of life of BC patients that develop pulmonary metastases are negatively impacted. The development of strategies to slow the growth and relieve the symptoms of BC lung metastases (BCLM) is thus an important goal in the management of BC. However, systemically administered first line small molecule chemotherapeutics have poor pharmacokinetic profiles and biodistribution to the lungs and significant off-target toxicity, severely compromising their effectiveness. In this work, we propose the local delivery of add-on immunotherapy to the lungs to support first line chemotherapy treatment of advanced BC. In a syngeneic murine model of BCLM, we show that local pulmonary administration (p.a.) of PLX-3397 (PLX), a colony-stimulating factor 1 receptor inhibitor (CSF-1Ri), is capable of overcoming physiological barriers of the lung epithelium, penetrating the tumor microenvironment (TME), and decreasing phosphorylation of CSF-1 receptors, as shown by the Western blot of lung tumor nodules. That inhibition is accompanied by an overall decrease in the abundance of protumorigenic (M2-like) macrophages in the TME, with a concomitant increase in the amount of antitumor (M1-like) macrophages when compared to the vehicle-treated control. These effects with PLX (p.a.) were achieved using a much smaller dose (1 mg\/kg, every other day) compared to the systemic doses typically used in preclinical studies (40\u2013800 mg\/kg\/day). As an additive in combination with intravenous (i.v.) administration of paclitaxel (PTX), PLX (p.a.) leads to a decrease in tumor burden without additional toxicity. These results suggested that the proposed immunochemotherapy, with regional pulmonary delivery of PLX along with the i.v. standard of care chemotherapy, may lead to new opportunities to improve treatment, quality of life, and survival of patients with BCLM.<\/jats:p>","DOI":"10.1021\/acs.molpharmaceut.0c00983","type":"journal-article","created":{"date-parts":[[2020,11,10]],"date-time":"2020-11-10T17:50:42Z","timestamp":1605030642000},"page":"4691-4703","source":"Crossref","is-referenced-by-count":20,"title":["Local Targeting of Lung-Tumor-Associated Macrophages\nwith Pulmonary Delivery of a CSF-1R Inhibitor for the Treatment of\nBreast Cancer Lung Metastases"],"prefix":"10.1021","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8418-9311","authenticated-orcid":true,"given":"Sulaiman\nS.","family":"Alhudaithi","sequence":"first","affiliation":[{"name":"Virginia Commonwealth University , , , ,","place":["Richmond, Virginia, United States, 23298"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2991-620X","authenticated-orcid":true,"given":"Rashed M.","family":"Almuqbil","sequence":"additional","affiliation":[{"name":"Virginia Commonwealth University , , , ,","place":["Richmond, Virginia, United States, 23298"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanming","family":"Zhang","sequence":"additional","affiliation":[{"name":"Virginia Commonwealth University , , , ,","place":["Richmond, Virginia, United States, 23298"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth R.","family":"Bielski","sequence":"additional","affiliation":[{"name":"Virginia Commonwealth University , , , ,","place":["Richmond, Virginia, United States, 23298"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Du","sequence":"additional","affiliation":[{"name":"Virginia Commonwealth University , , , ,","place":["Richmond, Virginia, United States, 23298"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatemah S.","family":"Sunbul","sequence":"additional","affiliation":[{"name":"Virginia Commonwealth University , , , ,","place":["Richmond, Virginia, United States, 23298"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula D.","family":"Bos","sequence":"additional","affiliation":[{"name":"Virginia Commonwealth University , , , ,","place":["Richmond, Virginia, United States, 23298"]},{"name":"Virginia Commonwealth University , , , ,","place":["Richmond, Virginia, United States, 23298"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandro R. P.","family":"da Rocha","sequence":"additional","affiliation":[{"name":"Virginia Commonwealth University , , , ,","place":["Richmond, Virginia, United States, 23298"]},{"name":"Virginia Commonwealth University , , , ,","place":["Richmond, Virginia, United States, 23298"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"316","published-online":{"date-parts":[[2020,11,10]]},"reference":[{"issue":"8","key":"2026081418205431500_cit1","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/nrc865","article-title":"Dissemination\nand Growth of Cancer\nCells in Metastatic Sites","volume":"2","author":"Chambers","year":"2002","journal-title":"Nat. Rev. Cancer"},{"issue":"1\u20132","key":"2026081418205431500_cit2","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1615\/CritRevOncog.v18.i1-2.40","article-title":"On the\nOrigin of Cancer Metastasis","volume":"18","author":"Seyfried","year":"2013","journal-title":"Crit. Rev. Oncog."},{"issue":"7","key":"2026081418205431500_cit3","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.3390\/cancers11071010","article-title":"Lung-Seeking\nMetastases","volume":"11","author":"Stella","year":"2019","journal-title":"Cancers"},{"issue":"10","key":"2026081418205431500_cit4","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.1200\/JCO.2003.08.132","article-title":"Primary Metastatic\nOsteosarcoma: Presentation and Outcome of Patients Treated on Neoadjuvant\nCooperative Osteosarcoma Study Group Protocols","volume":"21","author":"Kager","year":"2003","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"2026081418205431500_cit5","doi-asserted-by":"publisher","first-page":"435","DOI":"10.7150\/thno.13896","article-title":"A PH-Responsive Host-Guest\nNanosystem Loading Succinobucol Suppresses Lung Metastasis of Breast\nCancer","volume":"6","author":"Dan","year":"2016","journal-title":"Theranostics"},{"issue":"20","key":"2026081418205431500_cit6","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1056\/NEJMra1001389","article-title":"Triple-Negative\nBreast Cancer","volume":"363","author":"Foulkes","year":"2010","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"2026081418205431500_cit7","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1002\/cam4.1370","article-title":"Risk Factors and Survival Outcomes\nin Patients with Breast Cancer and Lung Metastasis: A Population-Based\nStudy","volume":"7","author":"Xiao","year":"2018","journal-title":"Cancer Med."},{"issue":"1","key":"2026081418205431500_cit8","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/S1470-2045(19)30689-8","article-title":"Atezolizumab\nplus Nab-Paclitaxel as First-Line Treatment for Unresectable, Locally\nAdvanced or Metastatic Triple-Negative Breast Cancer (IMpassion130):\nUpdated Efficacy Results from a Randomised, Double-Blind, Placebo-Controlled,\nPhase 3 Trial","volume":"21","author":"Schmid","year":"2020","journal-title":"Lancet Oncol."},{"issue":"5","key":"2026081418205431500_cit9","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1097\/COC.0000000000000671","article-title":"First-Line Treatment\nWith Atezolizumab Plus Nab-Paclitaxel\nfor Advanced Triple-Negative Breast Cancer: A Cost-Effectiveness Analysis","volume":"43","author":"Weng","year":"2020","journal-title":"Am. J. Clin. Oncol."},{"issue":"6","key":"2026081418205431500_cit10","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1007\/s40265-020-01295-y","article-title":"Atezolizumab (in\nCombination with Nab-Paclitaxel):\nA Review in Advanced Triple-Negative Breast Cancer","volume":"80","author":"Kang","year":"2020","journal-title":"Drugs"},{"issue":"3","key":"2026081418205431500_cit11","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1093\/annonc\/mdy518","article-title":"Pembrolizumab Monotherapy\nfor Previously Untreated, PD-L1-Positive, Metastatic Triple-Negative\nBreast Cancer: Cohort B of the Phase II KEYNOTE-086 Study","volume":"30","author":"Adams","year":"2019","journal-title":"Annals of Oncology"},{"issue":"6","key":"2026081418205431500_cit12","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1038\/aps.2016.166","article-title":"Dual-Targeted Hybrid\nNanoparticles\nof Synergistic Drugs for Treating Lung Metastases of Triple Negative\nBreast Cancer in Mice","volume":"38","author":"Zhang","year":"2017","journal-title":"Acta Pharmacol. Sin."},{"issue":"5","key":"2026081418205431500_cit13","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1007\/s13346-018-0551-3","article-title":"Metastatic and Triple-Negative\nBreast Cancer: Challenges and Treatment Options","volume":"8","author":"Al-Mahmood","year":"2018","journal-title":"Drug Delivery Transl. Res."},{"issue":"22","key":"2026081418205431500_cit14","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1056\/NEJMoa1809615","article-title":"Atezolizumab\nand Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer","volume":"379","author":"Schmid","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"2026081418205431500_cit15","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1056\/NEJMoa1910549","article-title":"Pembrolizumab\nfor Early Triple-Negative Breast Cancer","volume":"382","author":"Schmid","year":"2020","journal-title":"N.\nEngl. J. Med."},{"issue":"328","key":"2026081418205431500_cit16","doi-asserted-by":"publisher","first-page":"328rv4","DOI":"10.1126\/scitranslmed.aad7118","article-title":"PD-L1 (B7-H1) and PD-1 Pathway Blockade\nfor Cancer Therapy: Mechanisms, Response Biomarkers and Combinations","volume":"8","author":"Zou","year":"2016","journal-title":"Sci. Transl. Med."},{"issue":"1","key":"2026081418205431500_cit17","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1186\/s13045-019-0779-5","article-title":"Immune Checkpoint Inhibitors of PD-L1\nas Cancer Therapeutics","volume":"12","author":"Akinleye","year":"2019","journal-title":"J. Hematol. Oncol."},{"issue":"5","key":"2026081418205431500_cit18","doi-asserted-by":"publisher","first-page":"560","DOI":"10.3978\/j.issn.2218-6751.2015.06.06","article-title":"Immune Checkpoint Inhibitors\nin Clinical Practice: Update on Management\nof Immune-Related Toxicities","volume":"4","author":"Villadolid","year":"2015","journal-title":"Transl Lung Cancer\nRes."},{"issue":"39","key":"2026081418205431500_cit19","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1200\/EDBK_240837","article-title":"Mechanisms\nof Resistance to Immune Checkpoint Blockade: Why Does Checkpoint Inhibitor\nImmunotherapy Not Work for All Patients?","author":"Fares","year":"2019","journal-title":"American\nSociety of Clinical Oncology Educational Book"},{"issue":"1","key":"2026081418205431500_cit20","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1097\/PPO.0000000000000303","volume":"24","author":"Nowicki","year":"2018","journal-title":"Cancer\nJ."},{"key":"2026081418205431500_cit21","unstructured":"FDA Issues\nAlert about Efficacy and Potential Safety Concerns with Atezolizumab\nin Combination with Paclitaxel for Treatment of Breast Cancer. FDA. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-issues-alert-about-efficacy-and-potential-safety-concerns-atezolizumab-combination-paclitaxel."},{"key":"2026081418205431500_cit22","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s40425-017-0257-y","article-title":"Colony-Stimulating\nFactor 1 Receptor (CSF1R) Inhibitors\nin Cancer Therapy","volume":"5","author":"Cannarile","year":"2017","journal-title":"J. Immunother Cancer"},{"issue":"7","key":"2026081418205431500_cit23","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/nrclinonc.2016.217","article-title":"Tumor-Associated\nMacrophages as Treatment Targets in Oncology","volume":"14","author":"Mantovani","year":"2017","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"13","key":"2026081418205431500_cit24","doi-asserted-by":"publisher","first-page":"3241","DOI":"10.1158\/1078-0432.CCR-16-3122","article-title":"The Promise\nof Targeting Macrophages\nin Cancer Therapy","volume":"23","author":"Brown","year":"2017","journal-title":"Clin. Cancer Res."},{"issue":"16","key":"2026081418205431500_cit25","doi-asserted-by":"publisher","first-page":"1805","DOI":"10.1007\/s40265-019-01210-0","article-title":"Pexidartinib:\nFirst Approval","volume":"79","author":"Lamb","year":"2019","journal-title":"Drugs"},{"issue":"1","key":"2026081418205431500_cit26","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s10637-019-00745-z","article-title":"A Phase\nI Study of Pexidartinib, a Colony-Stimulating Factor 1 Receptor Inhibitor,\nin Asian Patients with Advanced Solid Tumors","volume":"38","author":"Lee","year":"2020","journal-title":"Invest. New Drugs"},{"issue":"5","key":"2026081418205431500_cit27","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1056\/NEJMoa1411366","article-title":"Structure-Guided Blockade of CSF1R Kinase in Tenosynovial\nGiant-Cell Tumor","volume":"373","author":"Tap","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"2026081418205431500_cit28","unstructured":"I-SPY\nTRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat\nBreast Cancer (I-SPY). Clinicaltrials.gov. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01042379?term=NCT01042379&draw=2&rank=1 (accessed October 22, 2020)."},{"issue":"6","key":"2026081418205431500_cit29","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.1021\/mp200292c","article-title":"Drug Resistance\nand Cellular Adaptation to Tumor Acidic PH Microenvironment","volume":"8","author":"Wojtkowiak","year":"2011","journal-title":"Mol. Pharmaceutics"},{"issue":"23","key":"2026081418205431500_cit30","doi-asserted-by":"publisher","first-page":"5591","DOI":"10.1242\/jcs.116392","article-title":"The Tumor\nMicroenvironment at a Glance","volume":"125","author":"Balkwill","year":"2012","journal-title":"J. Cell Sci."},{"issue":"5","key":"2026081418205431500_cit31","doi-asserted-by":"publisher","first-page":"2249","DOI":"10.1021\/acs.molpharmaceut.9b00261","article-title":"Targeted Delivery\nof Zoledronate\nto Tumor-Associated Macrophages for Cancer Immunotherapy","volume":"16","author":"Zang","year":"2019","journal-title":"Mol. Pharmaceutics"},{"issue":"24","key":"2026081418205431500_cit32","doi-asserted-by":"publisher","first-page":"7168","DOI":"10.1158\/0008-5472.CAN-14-2458","article-title":"Trafficking\nof T Cells into Tumors","volume":"74","author":"Slaney","year":"2014","journal-title":"Cancer Res."},{"issue":"7","key":"2026081418205431500_cit33","doi-asserted-by":"publisher","first-page":"2721","DOI":"10.1021\/acs.molpharmaceut.8b00237","article-title":"Modulating Macrophage\nPolarization through CCR2 Inhibition and Multivalent Engagement","volume":"15","author":"Deci","year":"2018","journal-title":"Mol. Pharmaceutics"},{"issue":"6","key":"2026081418205431500_cit34","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1016\/j.cell.2010.01.025","article-title":"Immunity,\nInflammation, and Cancer","volume":"140","author":"Grivennikov","year":"2010","journal-title":"Cell"},{"key":"2026081418205431500_cit35","doi-asserted-by":"publisher","first-page":"514","DOI":"10.3389\/fimmu.2014.00514","article-title":"From Monocytes to M1\/M2Macrophages: Phenotypical vs.\nFunctional Differentiation","volume":"5","author":"Italiani","year":"2014","journal-title":"Front. Immunol."},{"issue":"9","key":"2026081418205431500_cit36","doi-asserted-by":"publisher","first-page":"3525","DOI":"10.1021\/mp400216r","article-title":"Targeting of Tumor-Associated\nMacrophages Made Possible by PEG-Sheddable, Mannose-Modified Nanoparticles","volume":"10","author":"Zhu","year":"2013","journal-title":"Mol. Pharmaceutics"},{"key":"2026081418205431500_cit37","doi-asserted-by":"publisher","first-page":"489","DOI":"10.3389\/fimmu.2014.00489","article-title":"Functional Relationship\nbetween Tumor-Associated Macrophages and\nMacrophage Colony-Stimulating Factor as Contributors to Cancer Progression","volume":"5","author":"Laoui","year":"2014","journal-title":"Front. Immunol."},{"issue":"06","key":"2026081418205431500_cit38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4172\/2155-9899.1000379","article-title":"Colony-Stimulating Factor-1 Receptor in the Polarization\nof Macrophages: A Target for Turning Bad to Good Ones?","volume":"06","author":"Rovida","year":"2015","journal-title":"J. Clin. Cell. Immunol."},{"issue":"8","key":"2026081418205431500_cit39","doi-asserted-by":"publisher","first-page":"5245","DOI":"10.4049\/jimmunol.178.8.5245","article-title":"Granulocyte-Macrophage\nColony-Stimulating Factor (CSF) and Macrophage CSF-Dependent Macrophage\nPhenotypes Display Differences in Cytokine Profiles and Transcription\nFactor Activities: Implications for CSF Blockade in Inflammation","volume":"178","author":"Fleetwood","year":"2007","journal-title":"J. Immunol."},{"key":"2026081418205431500_cit40","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1158\/2159-8274.CD-10-0028","article-title":"Leukocyte\nComplexity Predicts Breast\nCancer Survival and Functionally Regulates Response to Chemotherapy","volume":"1","author":"DeNardo","year":"2011","journal-title":"Cancer Discovery"},{"issue":"43","key":"2026081418205431500_cit41","doi-asserted-by":"publisher","first-page":"6049","DOI":"10.1038\/onc.2017.261","article-title":"Inhibition of Colony\nStimulating Factor-1 Receptor Abrogates Microenvironment-Mediated\nTherapeutic Resistance in Gliomas","volume":"36","author":"Yan","year":"2017","journal-title":"Oncogene"},{"issue":"18","key":"2026081418205431500_cit42","doi-asserted-by":"publisher","first-page":"5057","DOI":"10.1158\/0008-5472.CAN-13-3723","article-title":"CSF1\/CSF1R\nBlockade Reprograms Tumor-Infiltrating Macrophages and Improves Response\nto T-Cell Checkpoint Immunotherapy in Pancreatic Cancer Models","volume":"74","author":"Zhu","year":"2014","journal-title":"Cancer Res."},{"issue":"1","key":"2026081418205431500_cit43","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1158\/0008-5472.CAN-13-1816","article-title":"Inhibition\nof CSF-1 Receptor Improves the Antitumor Efficacy of Adoptive Cell\nTransfer Immunotherapy","volume":"74","author":"Mok","year":"2014","journal-title":"Cancer Res."},{"key":"2026081418205431500_cit44","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1186\/1471-2407-10-112","article-title":"The M1 Form\nof Tumor-Associated Macrophages in Non-Small Cell Lung Cancer Is Positively\nAssociated with Survival Time","volume":"10","author":"Ma","year":"2010","journal-title":"BMC Cancer"},{"issue":"1","key":"2026081418205431500_cit45","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1183\/09031936.00065708","article-title":"Macrophages\nwithin NSCLC Tumour Islets Are Predominantly of a Cytotoxic M1 Phenotype\nAssociated with Extended Survival","volume":"33","author":"Ohri","year":"2009","journal-title":"Eur. Respir.\nJ."},{"issue":"9","key":"2026081418205431500_cit46","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0076147","article-title":"High-Infiltration of\nTumor-Associated\nMacrophages Predicts Unfavorable Clinical Outcome for Node-Negative\nBreast Cancer","volume":"8","author":"Zhang","year":"2013","journal-title":"PLoS One"},{"key":"2026081418205431500_cit47","unstructured":"A Study of PLX3397 in Patients with Unresectable\nor Metastatic KIT-Mutated\nMelanoma. Clinical Trials.gov.\n          https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02975700 (accessed Jun 25, 2020)."},{"issue":"3","key":"2026081418205431500_cit48","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1073\/pnas.0507321103","article-title":"A Landscape Effect in Tenosynovial Giant-Cell Tumor\nfrom Activation of CSF1 Expression by a Translocation in a Minority\nof Tumor Cells","volume":"103","author":"West","year":"2006","journal-title":"Proc. Natl. Acad. Sci. U. S.\nA."},{"key":"2026081418205431500_cit49","doi-asserted-by":"publisher","first-page":"175883591985423","DOI":"10.1177\/1758835919854238","article-title":"Phase Ib\nStudy of the Combination of Pexidartinib (PLX3397), a CSF-1R Inhibitor,\nand Paclitaxel in Patients with Advanced Solid Tumors","volume":"11","author":"Wesolowski","year":"2019","journal-title":"Ther Adv. Med. Oncol"},{"issue":"10197","key":"2026081418205431500_cit50","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1016\/S0140-6736(19)30764-0","article-title":"Pexidartinib versus Placebo for Advanced\nTenosynovial Giant Cell Tumour (ENLIVEN): A Randomised Phase 3 Trial","volume":"394","author":"Tap","year":"2019","journal-title":"Lancet"},{"key":"2026081418205431500_cit51","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1038\/s41523-019-0112-z","article-title":"A Case Report of\nVanishing Bile Duct Syndrome after\nExposure to Pexidartinib (PLX3397) and Paclitaxel","volume":"5","author":"Piawah","year":"2019","journal-title":"NPJ. Breast Cancer"},{"issue":"6","key":"2026081418205431500_cit52","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1038\/bjc.2014.62","article-title":"Low-Dose Inhalation of Interleukin-2 Bio-Chemotherapy\nfor the Treatment of Pulmonary Metastases in Melanoma Patients","volume":"110","author":"Posch","year":"2014","journal-title":"Br. J. Cancer"},{"issue":"137","key":"2026081418205431500_cit53","doi-asserted-by":"publisher","first-page":"137ra72","DOI":"10.1126\/scitranslmed.3003586","article-title":"Preexisting BCG-Specific\nT Cells Improve Intravesical\nImmunotherapy for Bladder Cancer","volume":"4","author":"Biot","year":"2012","journal-title":"Sci. Transl.\nMed."},{"key":"2026081418205431500_cit54","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.addr.2017.05.011","article-title":"Delivering Safer Immunotherapies\nfor Cancer","volume":"114","author":"Milling","year":"2017","journal-title":"Adv. Drug Delivery Rev."},{"key":"2026081418205431500_cit55","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/j.biopha.2018.11.122","article-title":"Nanosoldiers: A Promising\nStrategy to Combat Triple\nNegative Breast Cancer","volume":"110","author":"Pawar","year":"2019","journal-title":"Biomed. Pharmacother."},{"issue":"1","key":"2026081418205431500_cit56","doi-asserted-by":"publisher","first-page":"6704","DOI":"10.1038\/s41598-017-07162-3","article-title":"2-Dodecyl-6-Methoxycyclohexa-2,5-Diene-1,4-Dione\nInhibits the Growth and Metastasis of Breast Carcinoma in Mice","volume":"7","author":"Chen","year":"2017","journal-title":"Sci. Rep."},{"issue":"5","key":"2026081418205431500_cit57","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0198143","article-title":"MIND Model\nfor Triple-Negative\nBreast Cancer in Syngeneic Mice for Quick and Sequential Progression\nAnalysis of Lung Metastasis","volume":"13","author":"Ghosh","year":"2018","journal-title":"PLoS One"},{"issue":"1","key":"2026081418205431500_cit58","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1186\/s13046-018-0860-x","article-title":"Anti-Inflammatory Signaling by Mammary\nTumor Cells Mediates Prometastatic Macrophage Polarization in an Innovative\nIntraductal Mouse Model for Triple-Negative Breast Cancer","volume":"37","author":"Steenbrugge","year":"2018","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"8","key":"2026081418205431500_cit59","doi-asserted-by":"publisher","first-page":"2339","DOI":"10.1021\/mp300277f","article-title":"Multimodality Imaging\nof Breast Cancer Experimental Lung Metastasis\nwith Bioluminescence and a Monoclonal Antibody Dual-Labeled with 89Zr\nand IRDye 800CW","volume":"9","author":"Hong","year":"2012","journal-title":"Mol. Pharmaceutics"},{"issue":"6","key":"2026081418205431500_cit60","doi-asserted-by":"publisher","first-page":"4454","DOI":"10.3892\/mmr.2015.3258","article-title":"Lipopolysaccharide\nInduces Inflammation and Facilitates Lung Metastasis in a Breast Cancer\nModel via the Prostaglandin E2-EP2 Pathway","volume":"11","author":"Li","year":"2015","journal-title":"Mol. Med. Rep."},{"key":"2026081418205431500_cit61","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2015\/413076","article-title":"Paclitaxel\nand Its Evolving Role in the Management of Ovarian Cancer","volume":"2015","author":"Kampan","year":"2015","journal-title":"BioMed Res. Int."},{"key":"2026081418205431500_cit62","doi-asserted-by":"publisher","first-page":"9","DOI":"10.3389\/fimmu.2018.02629","article-title":"Targeting Macrophage-Recruiting Chemokines as a Novel\nTherapeutic Strategy to Prevent the Progression of Solid Tumors","volume":"9","author":"Argyle","year":"2018","journal-title":"Front. Immunol."},{"issue":"2","key":"2026081418205431500_cit63","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1042\/BST20150245","article-title":"Role of the Colony-Stimulating Factor (CSF)\/CSF-1 Receptor Axis in\nCancer","volume":"44","author":"Achkova","year":"2016","journal-title":"Biochem. Soc. Trans."},{"issue":"1","key":"2026081418205431500_cit64","doi-asserted-by":"publisher","first-page":"9","DOI":"10.3390\/molecules24010009","article-title":"Molecular Repolarisation of Tumour-Associated\nMacrophages","volume":"24","author":"Van\nDalen","year":"2019","journal-title":"Molecules"},{"issue":"3","key":"2026081418205431500_cit65","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1172\/JCI97642","article-title":"Antigen Delivery Targeted to Tumor-Associated\nMacrophages Overcomes Tumor Immune Resistance","volume":"129","author":"Muraoka","year":"2019","journal-title":"J. Clin. Invest."},{"issue":"16","key":"2026081418205431500_cit66","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1056\/NEJMoa1910836","article-title":"Five-Year\nSurvival with Combined Nivolumab and Ipilimumab in Advanced Melanoma","volume":"381","author":"Larkin","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"19","key":"2026081418205431500_cit67","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus\nChemotherapy for PD-L1\u2013Positive Non\u2013Small-Cell Lung\nCancer","volume":"375","author":"Reck","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"2026081418205431500_cit68","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1200\/JCO.2017.76.9901","article-title":"Durable Clinical\nBenefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair\u2013Deficient\/Microsatellite\nInstability\u2013High Metastatic Colorectal Cancer","volume":"36","author":"Overman","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"2026081418205431500_cit69","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1080\/14712598.2020.1752176","article-title":"Biologic Therapy\nfor Advanced Breast\nCancer: Recent Advances and Future Directions","volume":"20","author":"Tarantino","year":"2020","journal-title":"Expert Opin. Biol. Ther."},{"issue":"2","key":"2026081418205431500_cit70","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.thorsurg.2020.01.001","article-title":"Adjuvant\nand Neoadjuvant Immunotherapy in Non\u2013Small Cell Lung Cancer","volume":"30","author":"Broderick","year":"2020","journal-title":"Thoracic Surgery Clinics"},{"issue":"6382","key":"2026081418205431500_cit71","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1126\/science.aar4060","article-title":"Cancer Immunotherapy\nUsing Checkpoint Blockade","volume":"359","author":"Ribas","year":"2018","journal-title":"Science"},{"issue":"7","key":"2026081418205431500_cit72","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1007\/s00262-008-0455-z","article-title":"Local Therapy of\nCancer with Free IL-2","volume":"57","author":"Den\nOtter","year":"2008","journal-title":"Cancer Immunol. Immunother."},{"issue":"6","key":"2026081418205431500_cit73","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1510\/icvts.2008.194720","article-title":"Drug Uptake in a\nRodent Sarcoma Model after Intravenous Injection or Isolated Lung\nPerfusion of Free\/Liposomal Doxorubicin","volume":"8","author":"Cheng","year":"2009","journal-title":"Interactive\nCardio Vascular and Thoracic Surgery"},{"key":"2026081418205431500_cit74","doi-asserted-by":"publisher","first-page":"1","DOI":"10.5772\/24910","article-title":"The Airways:\nA Promising Route for the Pulmonary Delivery of Anticancer Agents","author":"Guilleminault","year":"2011","journal-title":"Advances in Cancer Therapy"},{"issue":"20","key":"2026081418205431500_cit75","doi-asserted-by":"publisher","first-page":"3476","DOI":"10.1016\/j.biomaterials.2009.03.010","article-title":"The Use\nof Biotinylated-EGF-Modified Gelatin Nanoparticle Carrier to Enhance\nCisplatin Accumulation in Cancerous Lungs via Inhalation","volume":"30","author":"Tseng","year":"2009","journal-title":"Biomaterials"},{"issue":"3","key":"2026081418205431500_cit76","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1089\/jamp.2008.0684","article-title":"Feasibility and Safety\nof Targeted Cisplatin Delivery to a Select\nLung Lobe in Dogs via the Aero Probe Intracorporeal Nebulization Catheter","volume":"21","author":"Selting","year":"2008","journal-title":"J. Aerosol Med. Pulm. Drug Delivery"},{"issue":"4","key":"2026081418205431500_cit77","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1158\/1078-0432.CCR-06-1096","article-title":"Phase I\nStudy of Inhaled Doxorubicin for Patients with Metastatic Tumors to\nthe Lungs","volume":"13","author":"Otterson","year":"2007","journal-title":"Clin. Cancer Res."},{"issue":"5","key":"2026081418205431500_cit78","doi-asserted-by":"crossref","first-page":"183","DOI":"10.14712\/fb2003049050183","article-title":"Efficacy and Safety of Inhaled Recombinant\nInterleukin-2 in High-Risk\nRenal Cell Cancer Patients Compared with Systemic Interleukin-2: An\nOutcome Study","volume":"49","author":"Huland","year":"2003","journal-title":"Folia Biol. (Praha)"},{"issue":"3","key":"2026081418205431500_cit79","doi-asserted-by":"publisher","first-page":"329","DOI":"10.3390\/cancers11030329","article-title":"The Position\nof Inhaled Chemotherapy in the Care of Patients with Lung Tumors:\nClinical Feasibility and Indications According to Recent Pharmaceutical\nProgresses","volume":"11","author":"Rosie\u0300re","year":"2019","journal-title":"Cancers"},{"issue":"8","key":"2026081418205431500_cit80","doi-asserted-by":"publisher","first-page":"2466","DOI":"10.1158\/1078-0432.CCR-09-3015","article-title":"Phase I\/II Study of Inhaled Doxorubicin\nCombined with Platinum-Based Therapy for Advanced Non-Small Cell Lung\nCancer","volume":"16","author":"Otterson","year":"2010","journal-title":"Clin. Cancer Res."},{"issue":"4","key":"2026081418205431500_cit81","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1002\/pbc.24438","article-title":"Inhaled Lipid Cisplatin\n(ILC) in the Treatment of Patients\nwith Relapsed\/Progressive Osteosarcoma Metastatic to the Lung","volume":"60","author":"Chou","year":"2013","journal-title":"Pediatr Blood Cancer"},{"key":"2026081418205431500_cit82","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.2147\/IJN.S29997","article-title":"Inhaled Chemotherapy\nin Lung Cancer: Future Concept of Nanomedicine","volume":"7","author":"Zarogoulidis","year":"2012","journal-title":"Int. J. Nanomed."},{"issue":"7","key":"2026081418205431500_cit83","doi-asserted-by":"publisher","first-page":"2319","DOI":"10.1158\/1078-0432.CCR-0929-3","article-title":"Clinical\nEvaluation of the Delivery and Safety of Aerosolized Liposomal 9-Nitro-20\u00ad(S)-Camptothecin\nin Patients with Advanced Pulmonary Malignancies","volume":"10","author":"Verschraegen","year":"2004","journal-title":"Clin. Cancer Res."},{"issue":"15","key":"2026081418205431500_cit84","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1093\/jnci\/86.15.1159","article-title":"Treatment of Patients\nwith Metastatic Melanoma with\nAutologous Tumor-Infiltrating Lymphocytes and Interleukin 2","volume":"86","author":"Rosenberg","year":"1994","journal-title":"J. Natl. Cancer Inst."},{"issue":"4A","key":"2026081418205431500_cit85","first-page":"2679","article-title":"Treatment\nof Pulmonary Metastatic\nRenal-Cell Carcinoma in 116 Patients Using Inhaled Interleukin-2 (IL-2)","volume":"19","author":"Huland","year":"1999","journal-title":"Anticancer Res."},{"issue":"15","key":"2026081418205431500_cit86","doi-asserted-by":"publisher","first-page":"4024","DOI":"10.1158\/1078-0432.CCR-10-0662","article-title":"INHALED\nGM-CSF FOR FIRST PULMONARY\nRECURRENCE OF OSTEOSARCOMA; EFFECTS ON DISEASE FREE SURVIVAL AND IMMUNOMODULATION:\nA REPORT FROM THE CHILDREN\u2019S ONCOLOGY GROUP","volume":"16","author":"Arndt","year":"2010","journal-title":"Clin. Cancer Res."},{"issue":"3","key":"2026081418205431500_cit87","doi-asserted-by":"publisher","first-page":"113","DOI":"10.3390\/pharmaceutics11030113","article-title":"Strategies\nto Enhance Drug Absorption\nvia Nasal and Pulmonary Routes","volume":"11","author":"Ghadiri","year":"2019","journal-title":"Pharmaceutics"},{"issue":"6","key":"2026081418205431500_cit88","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1038\/aps.2017.34","article-title":"Pulmonary Delivery of Nanoparticle\nChemotherapy for the Treatment of Lung Cancers: Challenges and Opportunities","volume":"38","author":"Mangal","year":"2017","journal-title":"Acta Pharmacol. Sin."},{"issue":"7","key":"2026081418205431500_cit89","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0040775","article-title":"The Interplay of\nLung Surfactant Proteins and Lipids\nAssimilates the Macrophage Clearance of Nanoparticles","volume":"7","author":"Ruge","year":"2012","journal-title":"PLoS One"},{"issue":"6","key":"2026081418205431500_cit90","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.1021\/acs.molpharmaceut.6b00187","article-title":"Combination Approach of YSA Peptide Anchored Docetaxel Stealth Liposomes\nwith Oral Antifibrotic Agent for the Treatment of Lung Cancer","volume":"13","author":"Patel","year":"2016","journal-title":"Mol. Pharmaceutics"},{"issue":"5","key":"2026081418205431500_cit91","doi-asserted-by":"publisher","first-page":"1648","DOI":"10.1021\/acs.molpharmaceut.0c00083","article-title":"Dendrimer Conjugation\nEnhances Tumor\nPenetration and Efficacy of Doxorubicin in Extracellular Matrix-Expressing\n3D Lung Cancer Models","volume":"17","author":"Almuqbil","year":"2020","journal-title":"Mol. Pharmaceutics"},{"issue":"17","key":"2026081418205431500_cit92","doi-asserted-by":"publisher","first-page":"E4041","DOI":"10.1073\/pnas.1720948115","article-title":"Macrophages\nImpede CD8 T Cells from Reaching Tumor Cells and Limit the Efficacy\nof Anti\u2013PD-1 Treatment","volume":"115","author":"Peranzoni","year":"2018","journal-title":"Proc. Natl. Acad.\nSci. U. S. A."},{"issue":"3","key":"2026081418205431500_cit93","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1158\/0008-5472.CAN-12-2731","article-title":"Targeting Tumor-Infiltrating\nMacrophages Decreases Tumor-Initiating Cells, Relieves Immunosuppression\nand Improves Chemotherapeutic Responses","volume":"73","author":"Mitchem","year":"2013","journal-title":"Cancer\nRes."},{"issue":"8","key":"2026081418205431500_cit94","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1158\/1535-7163.MCT-16-0866","article-title":"Colony-Stimulating\nFactor 1 Receptor\nBlockade Inhibits Tumor Growth by Altering the Polarization of Tumor-Associated\nMacrophages in Hepatocellular Carcinoma","volume":"16","author":"Ao","year":"2017","journal-title":"Mol.\nCancer Ther."},{"key":"2026081418205431500_cit95","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1158\/2326-6066.CIR-14-0232","article-title":"TH2-Polarized CD4\u00ad(+) T Cells and\nMacrophages Limit\nEfficacy of Radiotherapy","volume":"3","author":"Shiao","year":"2015","journal-title":"Cancer Immunol. Res."},{"issue":"4","key":"2026081418205431500_cit96","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1021\/mp300043f","article-title":"Partial Biodistribution and Pharmacokinetics\nof Isoniazid and Rifabutin Following Pulmonary Delivery of Inhalable\nMicroparticles to Rhesus Macaques","volume":"9","author":"Kumar\nVerma","year":"2012","journal-title":"Mol. Pharmaceutics"},{"issue":"16","key":"2026081418205431500_cit97","doi-asserted-by":"publisher","first-page":"3597","DOI":"10.1158\/1078-0432.CCR-14-2520","article-title":"Molecular Pathways: Activating T\nCells after Cancer Cell Phagocytosis from Blockade of CD47 \u201cDon\u2019t\nEat Me\u201d Signals","volume":"21","author":"McCracken","year":"2015","journal-title":"Clin. Cancer Res."},{"issue":"7","key":"2026081418205431500_cit98","doi-asserted-by":"publisher","first-page":"2518","DOI":"10.1021\/acs.molpharmaceut.0c00226","article-title":"Targeting\nPro-Tumoral Macrophages in Early Primary and Metastatic Breast Tumors\nwith the CD206-Binding MUNO Peptide","volume":"17","author":"Lepland","year":"2020","journal-title":"Mol. Pharmaceutics"},{"key":"2026081418205431500_cit99","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.addr.2017.04.010","article-title":"Progress in Tumor-Associated Macrophage\n(TAM)-Targeted Therapeutics","volume":"114","author":"Ngambenjawong","year":"2017","journal-title":"Adv. Drug Delivery\nRev."},{"key":"2026081418205431500_cit100","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.ebiom.2016.02.024","article-title":"Targeting\nMyeloid-Derived Suppressor Cells with Colony\nStimulating Factor-1 Receptor Blockade Can. Reverse Immune Resistance\nto Immunotherapy in Indoleamine 2,3-Dioxygenase-Expressing Tumors","volume":"6","author":"Holmgaard","year":"2016","journal-title":"E Bio Medicine"},{"key":"2026081418205431500_cit101","doi-asserted-by":"publisher","first-page":"828","DOI":"10.3389\/fimmu.2017.00828","article-title":"Reprogramming of Tumor-Associated\nMacrophages with Anticancer Therapies: Radiotherapy versus Chemo-\nand Immunotherapies","volume":"8","author":"Genard","year":"2017","journal-title":"Front. Immunol."},{"issue":"10","key":"2026081418205431500_cit102","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1038\/nm.3337","article-title":"CSF-1R Inhibition Alters Macrophage Polarization and\nBlocks Glioma Progression","volume":"19","author":"Pyonteck","year":"2013","journal-title":"Nat. Med."},{"key":"2026081418205431500_cit103","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/1757-2215-7-19","article-title":"A High M1\/M2 Ratio\nof Tumor-Associated Macrophages Is Associated with Extended Survival\nin Ovarian Cancer Patients","volume":"7","author":"Zhang","year":"2014","journal-title":"J. Ovarian Res."},{"key":"2026081418205431500_cit104","doi-asserted-by":"publisher","first-page":"9","DOI":"10.3389\/fonc.2019.01512","article-title":"Evaluating\nthe Polarization of Tumor-Associated\nMacrophages Into M1 and M2 Phenotypes in Human Cancer Tissue: Technicalities\nand Challenges in Routine Clinical Practice","volume":"9","author":"Jayasingam","year":"2020","journal-title":"Front. Oncol."}],"container-title":["Molecular Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/pubs.acs.org\/doi\/pdf\/10.1021\/acs.molpharmaceut.0c00983","content-type":"application\/pdf","content-version":"vor","intended-application":"unspecified"},{"URL":"https:\/\/pubs.acs.org\/mpohbp\/article-pdf\/17\/12\/4691\/13659545\/mp0c00983.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/pubs.acs.org\/mpohbp\/article-pdf\/17\/12\/4691\/13659545\/mp0c00983.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T22:23:16Z","timestamp":1786746196000},"score":1,"resource":{"primary":{"URL":"https:\/\/pubs.acs.org\/mpohbp\/article\/17\/12\/4691\/510194\/Local-Targeting-of-Lung-Tumor-Associated"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,10]]},"references-count":104,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2020,11,10]]},"published-print":{"date-parts":[[2020,12,7]]}},"URL":"https:\/\/doi.org\/10.1021\/acs.molpharmaceut.0c00983","relation":{},"ISSN":["1543-8384","1543-8392"],"issn-type":[{"value":"1543-8384","type":"print"},{"value":"1543-8392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,10]]}}}